Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Keview

被引:28
|
作者
Nobakht, Niloofar [1 ]
Hanna, Ramy M. [1 ,2 ]
Al-Baghdadi, Maha [1 ,3 ]
Ameen, Khalid Mohammed [1 ]
Arman, Farid [1 ,4 ]
Nobahkt, Ehsan [5 ]
Kamgar, Mohammad [1 ]
Rastogi, Anjay [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Nephrol, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Irvine, Dept Med, Div Nephrol, Orange, CA USA
[3] Univ Alabama, Dept Med, Huntsville Reg Campus, Huntsville, AL USA
[4] Univ Penn, Dept Med, Med Ctr, Philadelphia, PA USA
[5] George Washington Univ, Dept Med, Div Renal Dis & Hypertens, Washington, DC USA
关键词
RENAL CYST; SECONDARY ANALYSIS; EPITHELIAL-CELLS; TOLVAPTAN; ADPKD; PROGRESSION; VOLUME; GROWTH; INHIBITION; VASOPRESSIN;
D O I
10.1016/j.xkme.2019.11.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Polycystic kidney disease (PKD) is a multiorgan disorder resulting in fluid-filled cyst formation in the kidneys and other systems. The replacement of kidney parenchyma with an ever-increasing volume of cysts eventually leads to kidney failure. Recently, increased understanding of the pathophysiology of PKD and genetic advances have led to new approaches of treatment targeting physiologic pathways, which has been proven to slow the progression of certain types of the disease. We review the pathophysiologic patterns and recent advances in the clinical pharmacotherapy of autosomal dominant PKD. A multi-pronged approach with pharmacologic and nonpharmacologic treatments can be successfully used to slow down the rate of progression of autosomal dominant PKD to kidney failure. (C) 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
引用
收藏
页码:196 / 208
页数:13
相关论文
共 50 条
  • [31] Novel Treatments of Autosomal Dominant Polycystic Kidney Disease
    Mahnensmith, Rex L.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (05): : 831 - 836
  • [32] Cisterna Chyli in Autosomal Dominant Polycystic Kidney Disease
    Thimmappa, Nanda Deepa
    Blumenfeld, Jon D.
    Cerilles, Michelle Ann C.
    Dunning, Allison
    Donahue, Stephanie L.
    Bobb, Warren O.
    Zhang, Hong Lei
    Prince, Martin R.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2015, 41 (01) : 142 - 148
  • [33] New treatments for autosomal dominant polycystic kidney disease
    Chang, Ming-Yang
    Ong, Albert C. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (04) : 524 - 535
  • [34] Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
    Stayner, Cherie
    Brooke, Darby G.
    Bates, Michael
    Eccles, Michael R.
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (17) : 3081 - 3102
  • [35] Clinical burden of autosomal dominant polycystic kidney disease
    Hung, Peir-Haur
    Lin, Chien-Hung
    Hung, Kuan-Yu
    Muo, Chih-Hsin
    Chung, Mu-Chi
    Chang, Chao-Hsiang
    Chung, Chi-Jung
    AGING-US, 2020, 12 (04): : 3899 - 3910
  • [36] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Iijima, Hiroko
    Tada, Toshifumi
    Hashimoto, Mariko
    Nishimura, Takashi
    Kiriki, Masato
    Higashiura, Akiko
    Iwasaki, Aya
    Honda, Michino
    Nagasawa, Yasuyuki
    Yamakado, Koichiro
    JOURNAL OF MEDICAL ULTRASONICS, 2023, 50 (01) : 81 - 87
  • [37] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [38] Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Koch, Gary
    Ouyang, John
    McQuade, Robert D.
    Blais, Jaime D.
    Czerwiec, Frank S.
    Sergeyeva, Olga
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1930 - 1942
  • [39] Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges
    Chebib, Fouad T.
    Perrone, Ronald D.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (03): : 261 - 284
  • [40] Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
    Kim, Yaerim
    Han, Seungyeup
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (03): : 322 - 331